Why the study?
Does big endothelin-1 level predict major adverse cardiovascular events in patients with myocardial infarction younger than 35 years old?
Cohort (n=565)
Does big endothelin-1 level predict major adverse cardiovascular events in patients with myocardial infarction younger than 35 years old?
Results on big endothelin-1 not reported; leaves open its predictive value for MACE in young MI patients.
Background: Big endothelin-1 (ET-1) has been indicated to be a risk marker for cardiovascular disease and events. And the prevalence of myocardial infarction (MI) is increasing in younger patients. However, predictive value of big ET-1 for cardiovascular outcomes in very young MI patients has not been characterized. Purpose: To investigate whether big ET-1 can be a useful marker for predicting the future events in patients with myocardial infarction younger than 35 years old. Methods: Five hundred and sixty-five consecutive MI patients younger than 35 years of age were studied and followed up for 37.78±24.90 months. All patients underwent coronary angiography. The major adverse cardiovascular events (MACEs) consisted of all-cause death, non-fatal MI, stroke, revascularization and readmission for unstable angina and heart failure. Receiver operating characteristics (ROC) analysis was conducted to examine the predictive value of big ET-1 for MACEs. The event-free survival rate was calculated by the Kaplan–Meier method and compared by the log rank test.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2017) conducted a cohort in Myocardial infarction (n=565). Big endothelin-1 (ET-1) was evaluated on Major adverse cardiovascular events (all-cause death, non-fatal MI, stroke, revascularization and readmission for unstable angina and heart failure).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: